MatranaM.R., DuranC., ShettyA., XiaoL., AtkinsonB.J., CornP., PaglairoL.C., MillikanR.E., CharnsangaveC., JonaschE., TannirN.M.: Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer, 49: 3169–3175, 2013.
2.
EscudierB., EisenT., PortaC., PatardJ.J., KhooV., AlgabaF., MuldersP., KatajaV.; ESMO Guidelines Working Group Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, Suppl, 7: vii65–71, 2012.
3.
SternbergC.N., DavisI.D., MardiakJ., SzczylikC., LeeE., WagstaffJ., BarriosC.H., SalmanP., GladkovO.A., KavinaA., ZarbáJ.J., ChenM., McCannL., PanditeL., RoychowdhuryD.F., HawkinsR.E.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28: 1061–1068, 2010.
4.
IacovelliR., AlesiniD., PalazzoA., TrentaP., SantoniM., De MarchisL., CascinuS., NasoG., CortesiE.: Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev, 40: 271–275, 2014.
5.
McKayR.R., KroegerN., XieW., LeeJ.L., KnoxJ.J., BjarnasonG.A., MacKenzieM.J., WoodL., SrinivasS., VaishampayanU.N., RhaS.Y., PalS.K., DonskovF., TantravahiS.K., RiniB.I., HengD.Y., ChoueiriT.K.: Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol, 65: 577–584, 2013.
6.
SantoniM., SantiniD., MassariF., ContiA., IacovelliR., BurattiniL., TortoraG., FalconiM., MontironiR., CascinuS.: Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev, 33: 321–331, 2014.
7.
BuschJ., SeidelC., GoranovaI., ErberB., PetersR., FriedersdorffF., MagheliA., MillerK., GrünwaldV., WeikertS.: Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer, 50: 563–569, 2014.
8.
MolinaA.M., LinX., KorytowskyB., MatczakE., LechugaM.J., WiltshireR., MotzerR.J.: Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer, 50: 351–358, 2014.
9.
LocatelliM.C., MiedicoA., D'AntonaA., LongoG., MaggioniM., MaggioniA., TomboliniP., TabiadonD.: Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma. Tumori, 96: 478–482, 2010.
